Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menopausal Osteoporosis Clear all
Completed Not applicable Interventional

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

NCT00031811
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms, Osteoporosis
Interventions
raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 3, 2026, 11:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Raloxifene HCL, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 80 Years · Female only
Enrollment
7,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

NCT02589600
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions
Zoledronic acid, vitamin D, calcium, Saline
Drug · Dietary Supplement · Other
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Kensington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Patient- and Physician-Based Osteoporosis Education

NCT00073190
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal
Interventions
Osteoporosis Education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

NCT03710889
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk, Osteoporosis Fracture, Osteoporosis Localized to Spine, Osteoporosis, Age-Related, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Golden, Colorado • Gainesville, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

NCT02016716
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 3, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bindex for Osteoporosis Diagnostics

NCT03878732
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Bindex measurement
Diagnostic Test
Lead sponsor
Bone Index Finland Ltd
Industry
Eligibility
50 Years to 100 Years · Female only
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 3, 2026, 11:46 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 3, 2026, 11:46 PM EDT
Not listed Phase 3 Interventional

Comparative Efficacy, Safety, PK, and Immunogenicity Study

NCT05853354
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab
Biological
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

NCT01292187
View directory record Official record
Conditions
Osteopenia
Interventions
Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

NCT01796301
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romozosumab, Teriparatide
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Open Label Extension Study of PREOS

NCT00172133
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 (drug)
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 3, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Health in Bariatric Surgery Patients

NCT03331536
View directory record Official record
Conditions
Bariatric Surgery, Osteoporosis, Fractures, Bone, Roux En-Y Gastric Bypass, Sleeve Gastrectomy, Menopause, Premenopause
Interventions
Roux en Y Gastric Bypass Pre-menopausal, Roux en Y Gastric Bypass Post-menopausal, Sleeve Gastrectomy Pre-menopausal, Sleeve Gastrectomy Post-menopausal
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 3, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Alendronate, Calcium Citrate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808
View directory record Official record
Conditions
Osteopenia
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 3, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 3, 2026, 11:46 PM EDT